TrialLeukemia & lymphoma2021

A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Jonathan A Webster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.